Targeting protein–ligand neosurfaces with a generalizable deep learning tool
计算生物学
配体(生物化学)
计算机科学
深度学习
人工智能
数据科学
化学
生物
生物化学
受体
作者
Anthony Marchand,Stephen Buckley,Arne Schneuing,Martin Pačesa,Maddalena Elia,Pablo Gaínza,Evgenia Elizarova,Rebecca M. Neeser,Pao‐Wan Lee,Luc Reymond,Yangyang Miao,Leo Scheller,Sandrine Georgeon,Joseph Schmidt,Philippe Schwaller,Sebastian J. Maerkl,Michael M. Bronstein,Bruno E. Correia
Molecular recognition events between proteins drive biological processes in living systems1. However, higher levels of mechanistic regulation have emerged, in which protein–protein interactions are conditioned to small molecules2–5. Despite recent advances, computational tools for the design of new chemically induced protein interactions have remained a challenging task for the field6,7. Here we present a computational strategy for the design of proteins that target neosurfaces, that is, surfaces arising from protein–ligand complexes. To develop this strategy, we leveraged a geometric deep learning approach based on learned molecular surface representations8,9 and experimentally validated binders against three drug-bound protein complexes: Bcl2–venetoclax, DB3–progesterone and PDF1–actinonin. All binders demonstrated high affinities and accurate specificities, as assessed by mutational and structural characterization. Remarkably, surface fingerprints previously trained only on proteins could be applied to neosurfaces induced by interactions with small molecules, providing a powerful demonstration of generalizability that is uncommon in other deep learning approaches. We anticipate that such designed chemically induced protein interactions will have the potential to expand the sensing repertoire and the assembly of new synthetic pathways in engineered cells for innovative drug-controlled cell-based therapies10. A computational deep learning approach is used to design synthetic proteins that target the neosurfaces formed by protein–ligand interactions, with applications in the development of new therapeutic modalities such as molecular glues or cell-based therapies.